AI Market Mood: Stock Dashboard
SMMT
Fundamental
Company: Summit Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: -
P/E: -
EPS (ttm): -1.24
Insider Own: 86.17%
Shs Outstand: 744.44M
Perf Week: -10.21%
Market Cap: 12.02B
Forward P/E: -
EPS next Y: -0.91
Insider Trans: 0.20%
Shs Float: 102.73M
Perf Month: -13.65%
Enterprise Value: 11.79B
PEG: -
EPS next Q: -0.23
Inst Own: 14.12%
Short Float: 31.57%
Perf Quarter: -38.37%
Income: -921.61M
P/S: -
EPS this Y: -318.04%
Inst Trans: 12.95%
Short Ratio: 8.22
Perf Half Y: -37.37%
Sales: 0.00M
P/B: 62.69
EPS next Y Percentage: 29.67%
ROA: -241.08%
Short Interest: 32.44M
Perf YTD: -9.27%
Book/sh: 0.26
P/C: 50.33
EPS next 5Y: -
ROE: -292.49%
52W High: 36.91 -56.14%
Perf Year: -19.05%
Cash/sh: 0.32
P/FCF: -
EPS past 3/5Y: 31.56% -10.52%
ROIC: -472.69%
52W Low: 15.55 4.12%
Perf 3Y: 1456.73%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: -
Volatility W: 5.96%
Volatility M: 4.84%
Perf 5Y: 229.74%
Dividend TTM: -
EV/Sales: -
EPS Y/Y TTM: -348.63%
Oper. Margin: -
ATR (14): 1.05
Perf 10Y: 56.12%
Dividend Ex-Date: -
Quick Ratio: 3.80
Sales Y/Y TTM: -
Profit Margin: -
RSI (14): 31.73
Recom: 1.50
Dividend Gr. 3/5Y: - -
Current Ratio: 3.80
EPS Q/Q: -302.84%
SMA20: -10.27%
Beta: -1.39
Target Price: 33.85
Payout: -
Debt/Eq: 0.03
Sales Q/Q: -
SMA50: -17.12%
Rel Volume: 0.70
Prev Close: 16.45
Employees: 159
LT Debt/Eq: 0.01
Earnings: Oct 20 BMO
SMA200: -26.80%
Avg Volume: 3.95M
Price: 16.19
IPO: Mar 05, 2015
Option/Short: Yes / Yes
EPS/Sales Surpr.: -82.25% -
Trades:
Volume: 2,763,244
Change: -1.58%
Technical:
Latest News:
Citigroup Initiates Coverage of Summit Therapeutics (SMMT) with Buy Recommendation very bullish
SMMT
Summary: Citigroup initiated coverage of Summit Therapeutics with a Buy recommendation, projecting a 53.67% upside potential. Various funds and institutions are increasing their positions, with a bullish sentiment indicated by the put/call ratio of 0.35.
Full article2024-05-08T17:42:16Z